Literature DB >> 20549305

The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Ali T Taher1, Joseph Aoun, Pascale Salameh.   

Abstract

Venous thromboembolism (VTE) is a major public health issue that is frequently underestimated. The primary objective of this multinational survey was to identify patients at risk for VTE, and to define the rate of patients receiving appropriate prophylaxis in the Middle Eastern region. Standardized case report forms were filled by trained individuals on one predefined day in selected hospitals. Data were then entered and analyzed by independent biostatisticians. Risk was categorized according to American College of Chest Physicians (ACCP) guidelines, 2004. Logistic regressions were carried out to assess factors that determined VTE prophylaxis. 845 (37%) medical and 1421 (63%) surgical patients were eligible for the study. Patients were at low (4.2%), moderate (51.7%), high (9%) and very high risk (35.2%) for VTE. Any VTE prevention was given in 17.9, 41.7, 60.6 and 66.9% of respective risk categories, while ACCP guidelines were applied in 86.3, 41.1, 48.3 and 24.5% of these categories. Surgical patient type, immobility on admission, and contraceptive use were the most important drivers of VTE prophylaxis in those who were eligible to it (OR ≥ 2). Surgical patient type, immobility during hospitalization, existence of a VTE protocol and chronic heart failure were the most important drivers for VTE prophylaxis application in patients who were not eligible for it (OR ≥ 3). A concordance κ value of 0.16 was found between eligibility for VTE prophylaxis on one hand and its application in practice (P < 0.001). Risk factors for VTE and eligibility for VTE prophylaxis are common, but VTE prophylaxis and guidelines application are low.

Entities:  

Mesh:

Year:  2011        PMID: 20549305     DOI: 10.1007/s11239-010-0492-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  49 in total

1.  Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.

Authors:  E Oger
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

Review 2.  Prevention of venous thromboembolism.

Authors:  G P Clagett; F A Anderson; W Geerts; J A Heit; M Knudson; J R Lieberman; G J Merli; H B Wheeler
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 3.  A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals.

Authors:  Rebecca Tooher; Philippa Middleton; Clarabelle Pham; Robert Fitridge; Siohban Rowe; Wendy Babidge; Guy Maddern
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

4.  Preventing venous thromboembolism in acute medical patients.

Authors:  A Elis; M H Ellis
Journal:  QJM       Date:  2004-12

5.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.

Authors:  Victor F Tapson; Hervé Decousus; Mario Pini; Beng H Chong; James B Froehlich; Manuel Monreal; Alex C Spyropoulos; Geno J Merli; Rainer B Zotz; Jean-François Bergmann; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

6.  Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.

Authors:  Andrew F Shorr; William L Jackson; Brendan M Weiss; Lisa K Moores
Journal:  Blood Coagul Fibrinolysis       Date:  2007-06       Impact factor: 1.276

Review 7.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Risk stratification and utilisation of thrombo-embolism prophylaxis in a medical-surgical ICU: a hospital-based study.

Authors:  Khalid Ansari; Kuldeep Dalal; Mayur Patel
Journal:  J Indian Med Assoc       Date:  2007-09

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  An evaluation of practice pattern for venous thromboembolism prevention in Lebanese hospitals.

Authors:  Abeer A Zeitoun; Hani I Dimassi; Dania Y El Kary; Marwan G Akel
Journal:  J Thromb Thrombolysis       Date:  2008-12-27       Impact factor: 2.300

View more
  14 in total

1.  The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study.

Authors:  A A Zeitoun; J G Nassif; M M Zeineddine
Journal:  Int J Clin Pharm       Date:  2011-09-10

2.  Antithrombotic prophylaxis in the middle East.

Authors:  Samir Arnaout; Hanady R Samaha; Julien Succar; Imad Bou-Akl; Khaled M Musallam; Ali T Taher
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

3.  Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia.

Authors:  Abo-El-Nazar Essam; Galal Sharif; Fahad Al-Hameed
Journal:  Ann Thorac Med       Date:  2011-10       Impact factor: 2.219

Review 4.  What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article.

Authors:  Selma Regina de Oliveira Raymundo; Suzana Margareth Ajeje Lobo; Kassim Mohamede Kassim Hussain; Kassim Guzzon Hussein; Isabela Tobal Secches
Journal:  J Vasc Bras       Date:  2019-01-30

5.  Graduated compression stockings in prevention of venous thromboembolism among acutely ill medical patients aged over 75 years: a French national survey.

Authors:  Baptiste Gramont; Émilie Chalayer; Angélique Savall; Martin Killian; Thomas Celarier; Bernard Tardy
Journal:  Clin Interv Aging       Date:  2019-06-25       Impact factor: 4.458

6.  Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center.

Authors:  Ghazwa B Korayem; Omar A Alshaya; Norah S Alsubaie; Dalal A Alabdulkarim; Omar A Almohammed; Osamah M Alfayez; Majed S Al Yami
Journal:  Saudi Pharm J       Date:  2021-04-28       Impact factor: 4.330

7.  Venous thromboembolism prophylaxis in patients undergoing abdominal and pelvic cancer surgery: adherence and compliance to ACCP guidelines in DIONYS registry.

Authors:  Melkart Basile; Maroon Tohmeh; Negib Geahchan
Journal:  Springerplus       Date:  2016-09-13

8.  Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department.

Authors:  Ignacio Novo-Veleiro; Lucía Alvela-Suárez; Alba Costa-Grille; Javier Suárez-Dono; Fernando Ferrón-Vidan; Antonio Pose-Reino
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

9.  Thromboprophylaxis and mortality among patients who developed venous thromboembolism in seven major hospitals in Saudi Arabia.

Authors:  Fahad M Al-Hameed; Hasan M Al-Dorzi; Abdulelah I Qadhi; Amira Shaker; Farjah H Al-Gahtani; Fawzi F Al-Jassir; Galila F Zahir; Tarig S Al-Khuwaitir; Mohammed H Addar; Mohamed S Al-Hajjaj; Mohamed A Abdelaal; Essam Y Aboelnazar
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219

10.  A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs).

Authors:  Nibal Chamoun; Stephanie Matta; Sandrine Sarine Aderian; Rami Salibi; Pascale Salameh; Gaby Tayeh; Elie Haddad; Hady Ghanem
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.